6 月 4 日,艾伯维今天宣布,NMPA 已批准乌帕替尼缓释片(15 毫克,每日一次,商品名瑞福)用于治疗巨细胞动脉炎(GCA)成人患者。该批准距其在美国和欧盟获批仅一个多月,这使得乌帕替尼缓释片成为目前中国首个且唯一获批用于治疗巨细胞动脉炎(GCA)成年患者的口服 JAK 抑制剂。来源:艾伯维官微GCA 是一种免疫介导炎症性疾病,会导致颞动脉和其他颅动脉、主动脉以及其他大中型动脉发炎。GCA ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.